Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide in Stage 4/M Neuroblastoma
NCT03503864Phase 2Active, not recruiting
- Start
- Jun 2017
- Primary completion
- Aug 2023
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide in neuroblastoma. Primary endpoint: Objective Response Rate. Started Jun 2017; status: active, not recruiting.
02
Drugs
arsenic trioxide
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT03503864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03503864.